Insights into PPARγ phosphorylation and its inhibition mechanism

Roberta Montanari, Davide Capelli, Keiko Yamamoto, Hirono Awaishima, Kimina Nishikata, Arjan Barendregt, Albert J R Heck, Fulvio Loiodice, Fabio Altieri, Alessandro Paiardini, Alessandro Grotessi, Luciano Pirone, Emilia Maria Pedone, Franck Peiretti, Jean Michel Brunel, Toshimasa Itoh, Giorgio Pochetti

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

PPARγ represents a key target for the treatment of type II diabetes and metabolic syndrome. Synthetic antidiabetic drugs activating PPARγ are accompanied by serious undesirable side effects related to their agonism. In the search for new PPARγ regulators, inhibitors of PPARγ phosphorylation on S245 mediated by CDK5 represent an opportunity for the development of an improved generation of anti-diabetic drugs acting through this nuclear receptor. We have employed a multi-disciplinary approach, including protein-protein docking, X-ray, NMR, HDX, MD simulations and site-directed mutagenesis to investigate conformational changes in PPARγ that impair the ability of CDK5 to interact with PPARγ and hence inhibit PPARγ phosphorylation. Finally, we describe an alternate inhibition mechanism adopted by a ligand bound far from the phosphorylation site.

Original languageEnglish
Pages (from-to)4811–4823
JournalJournal of Medicinal Chemistry
Volume63
Issue number9
DOIs
Publication statusPublished - 2 Apr 2020

Fingerprint

Dive into the research topics of 'Insights into PPARγ phosphorylation and its inhibition mechanism'. Together they form a unique fingerprint.

Cite this